- cafead   Jul 01, 2024 at 11:12: AM
via Sanofi has reported the latest data from a Phase II clinical trial of a cluster of differentiation 40 ligand (CD40L) monoclonal antibody, frexalimab, in patients with relapsing multiple sclerosis (MS).
article source
article source